Pfizer Other Share Holders Equity 2010-2025 | PFE
Pfizer other share holders equity from 2010 to 2025. Other share holders equity can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Pfizer other share holders equity for the quarter ending June 30, 2025 was $0M, a 0% increase year-over-year.
- Pfizer other share holders equity for 2024 was $0B, a 0% decline from 2023.
- Pfizer other share holders equity for 2023 was $0B, a 0% decline from 2022.
- Pfizer other share holders equity for 2022 was $0B, a 0% decline from 2021.
Pfizer Annual Other Share Holders Equity
(Millions of US $) |
| 2024 |
$0 |
| 2023 |
$0 |
| 2022 |
$0 |
| 2021 |
$0 |
| 2020 |
$0 |
| 2019 |
$0 |
| 2018 |
$0 |
| 2017 |
$0 |
| 2016 |
$0 |
| 2015 |
$0 |
| 2014 |
$0 |
| 2013 |
$0 |
| 2012 |
$0 |
| 2011 |
$-3 |
| 2010 |
$-7 |
| 2009 |
$-333 |
Pfizer Quarterly Other Share Holders Equity
(Millions of US $) |
| 2025-06-30 |
|
| 2025-03-31 |
|
| 2024-12-31 |
|
| 2024-09-30 |
|
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
|
| 2023-09-30 |
|
| 2023-06-30 |
|
| 2023-03-31 |
|
| 2022-12-31 |
|
| 2022-09-30 |
|
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
|
| 2021-09-30 |
|
| 2021-06-30 |
|
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
|
| 2017-03-31 |
|
| 2016-12-31 |
|
| 2016-09-30 |
|
| 2016-06-30 |
|
| 2016-03-31 |
|
| 2015-12-31 |
|
| 2015-09-30 |
|
| 2015-06-30 |
|
| 2015-03-31 |
|
| 2014-12-31 |
|
| 2014-09-30 |
|
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-12-31 |
|
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
$-1 |
| 2012-12-31 |
|
| 2012-09-30 |
$-2 |
| 2012-06-30 |
$-2 |
| 2012-03-31 |
$-2 |
| 2011-12-31 |
$-3 |
| 2011-09-30 |
$-3 |
| 2011-06-30 |
$-3 |
| 2011-03-31 |
$-6 |
| 2010-12-31 |
$-7 |
| 2010-09-30 |
$-8 |
| 2010-06-30 |
$-25 |
| 2010-03-31 |
$-89 |
| 2009-12-31 |
$-333 |
| 2009-09-30 |
$-298 |
| 2009-06-30 |
$-304 |
| 2009-03-31 |
$-285 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$140.774B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
